CLINICAL TRIALS PROFILE FOR PANTOPRAZOLE SODIUM

All Clinical Trials for PANTOPRAZOLE SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00141817 ↗	Study Evaluating Pantoprazole in Children With GERD	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2005-08-01	The purpose of this study is to characterize the PK profile, safety and tolerability of single and multiple doses of pantoprazole in children aged 1 through 11 years with endoscopically proven GERD.
NCT00259012 ↗	Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD	Completed	Nycomed	Phase 3	2005-11-01	The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles to determine the safety and tolerability of single and multiple doses of pantoprazole in infants aged 1 through 11 months.
NCT00259012 ↗	Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2005-11-01	The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles to determine the safety and tolerability of single and multiple doses of pantoprazole in infants aged 1 through 11 months.
NCT00300755 ↗	Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)	Completed	Nycomed	Phase 3	2006-05-01	To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
NCT00300755 ↗	Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-05-01	To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
NCT00312806 ↗	Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)	Completed	Takeda	Phase 3	2006-05-01	The aim of the present study is to identify factors (such as symptom patterns and symptom scores) that influence the response to treatment with pantoprazole using different evaluation methods (e.g., ReQuest™ questionnaire, patient and investigator assessment). Pantoprazole will be administered once daily in the morning at one dose level. The study duration consists of a treatment period of 8 weeks. The study will provide further data on safety and tolerability of pantoprazole.

Clinical Trial Conditions for PANTOPRAZOLE SODIUM

Condition Name

Condition Name for PANTOPRAZOLE SODIUM
Intervention	Trials
Gastroesophageal Reflux	7
Healthy	7
Atrial Fibrillation	1
Immunosuppression	1

Condition MeSH

Condition MeSH for PANTOPRAZOLE SODIUM
Intervention	Trials
Gastroesophageal Reflux	8
Esophagitis, Peptic	5
Malnutrition	3
Hemorrhage	2

Clinical Trial Locations for PANTOPRAZOLE SODIUM

Trials by Country

Trials by Country for PANTOPRAZOLE SODIUM
Location	Trials
United States	111
Canada	10
India	7
Germany	4
South Africa	4

Trials by US State

Trials by US State for PANTOPRAZOLE SODIUM
Location	Trials
Texas	7
Kentucky	6
New York	5
Illinois	5
Florida	5

Clinical Trial Progress for PANTOPRAZOLE SODIUM

Clinical Trial Phase

Clinical Trial Phase for PANTOPRAZOLE SODIUM
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	8
Phase 2	1

Clinical Trial Status

Clinical Trial Status for PANTOPRAZOLE SODIUM
Clinical Trial Phase	Trials
Completed	21
Unknown status	1
Not yet recruiting	1

Clinical Trial Sponsors for PANTOPRAZOLE SODIUM

Sponsor Name

Sponsor Name for PANTOPRAZOLE SODIUM
Sponsor	Trials
Wyeth is now a wholly owned subsidiary of Pfizer	7
Nycomed	2
Teva Pharmaceuticals USA	2

Sponsor Type

Sponsor Type for PANTOPRAZOLE SODIUM
Sponsor	Trials
Industry	22
Other	7